To evaluate the effect of a Persian medicine product, containing silk, on the incidence of pregnancy in infertile women with polycystic ovary syndrom

To evaluate the effect of a Persian medicine product, containing silk, on the incidence of pregnancy in infertile women with polycystic ovary syndrome-A Randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221009056122N1

Enrollment

Registered

2022-11-01

Start date

2022-11-22

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility in women with polycystic ovary syndrome. Female infertility associated with anovulation

Interventions

Intervention 1: Intervention group: the intervention group, in addition to the common ovulation-stimulating drug, letrozole 2.5 mg twice (5 mg) once a day from the third to the seventh day of the mens

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Infertile women suffering from polycystic ovary syndrome referred to Rehane Infertility Center, Nekoui Hospital, Qom. Informed consent to enter the plan The period of infertility is at least 1 year and at most 5 years BMI less than 30 kg/m2

Exclusion criteria

Exclusion criteria: Male factor Infertility Tubular infertility other types of ovarian cysts except for PCO Endometriosis Premature ovarian failure (POF) and decreased ovarian reserve (DOR) Underlying and systemic disease and malignancy Breast diseases such as breast cysts Liver, kidney, joint and rheumatic disorders Other diseases including metabolic diseases such as diabetes and endocrine disorders including uncontrolled hypothyroidism, hyperprolactinemia, and Cushing's disease Breast diseases such as breast cysts Liver, kidney, joint and rheumatic disorders Other diseases including metabolic diseases such as diabetes and endocrine disorders including uncontrolled hypothyroidism, hyperprolactinemia, and Cushing's disease Other diseases include metabolic diseases such as diabetes and endocrine disorders including uncontrolled hypothyroidism, hyperprolactinemia, and Cushing's disease

Design outcomes

Primary

Measure	Time frame
Chemical pregnancy. Timepoint: After the first delay in menstruation, the fourth week of the menstruation cycle. Method of measurement: Serum ?-hCG meausurment.	—

Secondary

Measure	Time frame
Clinical pregnancy. Timepoint: After a positive serum ?-hCG test, the fifth to sixth week of the menstruation cycle. Method of measurement: Observing fetal heart rate on ultrasound.;The level of anxiety. Timepoint: The beginning and end of the intervention. Method of measurement: Anxiety score in Beck's questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBatoul Khayatzadeh

Ghoum University of Medical Sciences

bkhaiatzadeh@muq.ac.ir+98 25 3776 4073

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026